CNS pipeline · person
Robert Barrow, MS
Chief Executive Officer and Board Director of Definium Therapeutics, appointed CEO in 2021 (previously Chief Development Officer and interim CEO). A pharmaceutical executive with over a decade leading CNS drug development; formerly head of drug development at Usona Institute, where he led work that secured Breakthrough Therapy Designation for psilocybin in major depressive disorder, and COO of Olatec Therapeutics. MS in Pharmacology from The Ohio State University; BS from Wake Forest University.
- 1 company
Courtesy Definium Therapeutics
Current roles
- Definium Therapeutics, Inc.Chief Executive Officer · Executive
- Definium Therapeutics, Inc.Board Director · Board
Appears with
People sharing a company with Robert.
- Andreas Krebs · Definium Therapeutics, Inc.
- Brandi Roberts · Definium Therapeutics, Inc.
- Carol A. Vallone · Definium Therapeutics, Inc.
- Daniel R. Karlin · Definium Therapeutics, Inc.
- Gregg Pratt · Definium Therapeutics, Inc.
- Mark Sullivan · Definium Therapeutics, Inc.
- Matt Wiley · Definium Therapeutics, Inc.
- Maurizio Fava · Definium Therapeutics, Inc.
- Robert C. Malenka · Definium Therapeutics, Inc.
- Roger Adsett · Definium Therapeutics, Inc.
- Stephanie Fagan · Definium Therapeutics, Inc.
- Suzanne Bruhn · Definium Therapeutics, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.